Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of patients with accelerated/blast-phase MPNs that received allogeneic stem-cell transplant in the current era of myeloid therapies
    Meeting Abstract

    Patel, A. A.; Yoon, J. J.; Johnston, H.; Davidson, M. B.; Viswabandya, A.; Shallis, R. M.; Chen, E. C.; Burkart, M.; Oh, T. S.; Iyer, S. G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Sustained efficacy and safety with asciminib (ASC) after almost 4 years of median follow-up from ASCEMBL, a phase 3 study of ASC vs bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): An end of study treatment (EOS Tx) update, including results from switch population
    Meeting Abstract

    Mauro, M.; Minami, Y.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D. W.; Apperley, J. F.; Cortes, J.; Abdo, A. N. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • HJKC3-0006: Outcome of patients with CML treated on second line or later therapy in routine clinical practice
    Meeting Abstract

    Thompson, J. E.; Gao, Y.; Visotcky, A.; Flynn, K. E.; Mauro, M.; Giever, E.; Baim, A.; Akinola, I.; Larson, R.; Jamy, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • HJKC3-007: Outcomes of patients with chronic myeloid leukemia in chronic phase treated with asciminib and other tyrosine kinase inhibitors in routine clinical practice
    Meeting Abstract

    Mauro, M.; Atallah, E. L.; Thompson, J. E.; Gao, Y.; Visotcky, A.; Giever, E.; Baim, A.; Akinola, I.; Larson, R. A.; Jamy, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1a/b trial of luxeptinib (CG-806) in patients with relapsed/refractory B-cell malignancies or acute myeloid leukemia and evaluation of new G3 formulation
    Meeting Abstract

    Goldberg, A. D.; Samaniego, F.; Ohanian, M.; Koller, P. B.; Chandhok, N. S.; Sadiq, A. A.; Mahadevan, D.; Cherry, M. A.; Altman, J. K.; Burke, J. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comparative analysis of clinical outcomes and healthcare resource utilization (HRU) in patients (pts) with newly diagnosed (nd) acute myeloid leukemia (aml) unfit for high-intensity chemotherapy treated with venetoclax (VEN) vs other therapies: Results from the AML real world evidence (ARC) initiative
    Meeting Abstract

    Desai, P.; Garcia, J. S.; Zeidner, J. F.; Abedin, S.; Wolach, O.; Vachhani, P.; Moshe, Y.; Pollyea, D. A.; Lai, C.; LeBlanc, T. W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemias: Efficacy and safety results from the AUGMENT-101 phase 1/2 study
    Meeting Abstract

    Aldoss, I.; Issa, G. C.; Thirman, M. J.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G.; Perl, A.; Dickens, D.; McMahon, C. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of type of hypomethylating agent (HMA) used on outcomes of patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) - A large, multicenter, retrospective analysis
    Meeting Abstract

    Bewersdorf, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term results from the OPTIC trial: A dose-optimization study of 3 starting doses of ponatinib
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Undurraga, S.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Influence of pre-treatment features and therapy choice by physicians on overall survival in older adults with acute myeloid leukemia: A report from the beat AML master trial
    Meeting Abstract

    Borate, U. M.; Huang, Y.; Welkie, R. L.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; more...
    Blood (2023)

    Fulltext@MSK | Save